Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,291 across all filing types
Latest filing 2019-09-16 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
持股5%以上股东减持股份进展公告
Major Shareholding Notification Classification · 100% confidence The document is a shareholder announcement regarding the progress of a shareholding reduction by a shareholder holding more than 5% of the company's shares. It details the number of shares held before and after the reduction, the methods of reduction, and the impact on company control. There are no financial statements or comprehensive financial data presented. The document is a formal disclosure of a major shareholding change, specifically a reduction in shares held by a significant shareholder. This fits the definition of a Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding changes, not a full report or earnings release.
2019-09-16 Chinese
关于控股股东减持公司可转换公司债券的提示性公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement regarding the reduction of holdings in convertible bonds by the controlling shareholder of the company. It details the amounts and dates of the bond sales and the remaining holdings. The content focuses on shareholding changes related to convertible bonds, which is a capital structure change. The document is short (985 characters) and is an announcement rather than a detailed financial report or earnings release. It does not contain financial statements or management discussion. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes including convertible bond holdings changes.
2019-09-11 Chinese
使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Zhengzhou Antu Biological Engineering Co., Ltd. regarding the progress of cash management using idle funds. It details the company's purchase and management of various financial products such as open-ended wealth management products and structured deposits, including specific amounts, dates, and returns. The document is relatively short (2254 characters) and focuses on updates about financing activities related to cash management and investment products. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. It is not a report publication announcement since it provides substantive information rather than just announcing a report's release. The content aligns with updates on company fundraising, financing activities, or capital structure changes, which fits the Capital/Financing Update (CAP) category.
2019-09-02 Chinese
使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the progress of cash management using idle raised funds. It details the purchase and redemption of financial products such as bank wealth management products and structured deposits, including amounts, dates, and yields. The document is relatively short (2407 characters) and focuses on updates about the company's use of idle raised funds for cash management, not a full financial report or audit. It does not contain comprehensive financial statements or detailed financial analysis. This fits the category of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. Therefore, the appropriate classification is CAP with high confidence.
2019-09-02 Chinese
关于全资子公司取得《药品经营许可证》和GSP证书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhengzhou Antu Bioengineering Co., Ltd. regarding its wholly-owned subsidiary obtaining renewed licenses: the Drug Business License and the Good Supply Practice (GSP) certificate. It details certificate numbers, validity periods, and confirms that this is a re-certification of expiring licenses. There is no financial data, no mention of financial results, no shareholder voting, no management changes, no legal proceedings, no capital changes, and no report publication. The document is a regulatory announcement about compliance and certification status. It fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2019-08-29 Chinese
首次公开发行限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the listing and circulation of restricted shares following the company's initial public offering (IPO). It details the number of shares becoming freely tradable, the dates involved, compliance with regulatory approvals, and includes a verification opinion from the sponsoring securities firm. There are no financial statements or detailed financial performance data present. The document is a formal disclosure about share circulation status rather than a financial report or earnings release. This fits the category of Share Issue/Capital Change announcements, which cover new share issues, stock listing changes, and related capital structure updates.
2019-08-26 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.